Abstract:Key Points Parkinson's disease is a progressive neurological disorder characterized primarily by motor symptoms that include rigidity, hypokinesia and tremor. The most pronounced neuropathological feature is a loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in dopamine levels in the target region, the striatum. In the substantia nigra, some neurons have intracytoplasmic inclusions known as Lewy bodies. In most patients, Parkinson's disease shows no clear inheritance and the cause of neurodegeneration is not known. Several disease mechanisms have been proposed, including oxidative stress and mitochondrial dysfunction. Some emphasis has been placed on the possibility that environmental toxins trigger these pathological changes. In the late 1990s, the discovery of the gene that causes a rare autosomal-dominant form of Parkinson's disease led to renewed interest in the search for pathogenic mechanisms. The mutated gene encodes α-synuclein, a synaptic protein of unknown function. It has been suggested that it plays a role in the recycling of vesicles that have released their neurotransmitter content into the synaptic cleft. Moreover, further rare forms of Parkinson's disease have been identified that result from mutations in parkin and ubiquitin carboxy-terminal hydrolase L1. These proteins participate in the ubiquitin–proteasome pathway, which is responsible for the degradation of unwanted proteins. We speculate why changes in these diverse genes lead to a neurodegenerative process that is relatively focused on dopamine-containing neurons, and emphasize the role of dopamine-dependent oxidative stress in this process. We believe that there are multiple aetiological triggers, resulting from either genetic changes or environmental insults, which share the same final common pathway to cell death in dopaminergic neurons. Increased levels of cytoplasmic dopamine in nigral neurons in Parkinson's disease patients might result in dopamine oxidation and the generation of reactive oxygen species that can damage and eventually kill these neurons. One pathway that might lead to these events involves impaired vesicular storage of dopamine. Recent experimental evidence shows that the expression of mutant α-synuclein in a human dopaminergic cell line increases cytoplasmic dopamine levels and raises the levels of superoxide radicals in the cytoplasm. Dopamine-induced oxidative stress, impaired synaptic vesicle function and misfolding of α-synuclein, due to mutations or to oxidative damage to this protein, might be components in a self-perpetuating vicious cycle that eventually leads to the demise of dopaminergic neurons.

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

Mitophagy Upregulation Occurs Early in the Neurodegenerative Process Mediated by α-Synuclein

Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

The role of polo-like kinases 2 in the proteasomal and lysosomal degradation of alpha-synuclein in neurons

High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast

Impairment of Mitochondria in Adult Mouse Brain Overexpressing Predominantly Full-Length, N-Terminally Acetylated Human α-Synuclein

Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease

Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α-Synuclein-Based Mouse Models of Parkinson's Disease.

α-Synuclein oligomers induce the loss of dopaminergic neurons via mitochondrial dysfunction and oxidative stress in an intragastric rotenone mouse model of Parkinson’s disease

Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease

Conditional Expression Of Parkinson'S Disease-Related Mutant Alpha-Synuclein In The Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration And Degradation Of Transcription Factor Nuclear Receptor Related 1

Synuclein Impairs Trafficking and Signaling of BDNF in a Mouse Model of Parkinson’s Disease

Templating of Monomeric Alpha-Synuclein Induces Inflammation and SNpc Dopamine Neuron Death in a Genetic Mouse Model of Synucleinopathy.

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

Neuropathology in Mice Expressing Human Alpha-Synuclein.

1 serine 129 phosphorylation reduces α-synuclein ’ s ability to regulate tyrosine hydroxylase and protein phosphatase 2 a in vitro and in vivo

Senescence and impaired DNA damage responses in alpha-synucleinopathy models

The ubiquitin pathway in Parkinson's disease